Clinical Trial Update: Immunogenicity and Safety of Comvigen (Bivalent) Vaccine [Phase 2]

View source ↗

Summary

Phase 2 trial update on immunogenicity and safety of the Comvigen (Bivalent) vaccine, focusing on safety and reactogenicity after a single dose.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunogenicity of Single Dose of Vaccine
• Safety of Single Dose of Vaccine

Drugs mentioned

• BIVALENT Pfizer/BNT Vaccine (Pfizer/BNT vaccine (bivalent formulation))
• Comvigen (Comvigen)

Snippet

Sponsor: Chulalongkorn University | Conditions: Safety of a Single Dose of COMVIGEN Vaccine, Reactogenicity of a Single Dose of COMVIGEN Vaccine | Phase 2 | Status: UNKNOWN